IWMF

The International Waldenstrom's Macroglobulinemia Foundation (IWMF) is a registered 501(c)(3) organization dedicated to support and educate everyone affected by Waldenstrom's macroglobulinemia (WM) to improve patient outcomes while advancing the search for a cure We bolster our community through research, support, and education.

About Waldenstrom's Macroglobulinemia

Waldenstrom's macroglobulinemia, also known as lymphoplasmacytic lymphoma (LPL), is a rare form of non-Hodgkin's lymphoma with no known cure. WM is considered a rare disease because there are only about 1,500-3,000 new cases per year in the US and 1,500-3,000 per year in Europe. Overall, WM comprises only 1-2% of all blood cancers. This rarity makes it tough for researchers to secure funding and for patients to connect with one another. That's where IWMF steps in.

Our Mission and Impact

Led by an all-volunteer board and a small staff, IWMF is a lean but mighty organization. Since 1994, we've made significant strides in understanding WM and improving patient prognosis. Our efforts have helped fund the rationale for using BTK inhibitors in WM, leading to ibrutinib's approval as the first drug specifically for WM treatment.

Services and Support

As we continue to fund and push for research toward a cure, our support programs assist patients, caregivers, and medical professionals worldwide. Through our programs, WM community members can connect with others with the disease, learn about the latest treatments, find expert physicians, and access information to help them and their families live their best lives, every step of the way.

Get Involved

Join IWMF and support programs that change lives and empower patients. Visit iwmf.com to learn more.

Every step we take together brings us that much closer to a cure..